Global Bovine Heparin Market, valued at USD 4,722.2 million in 2023, is poised for steady expansion with projections reaching USD 5,682.4 million by 2030, growing at a CAGR of 2.7%. While the market demonstrates resilience, its trajectory has been shaped by recent global disruptions, including supply chain adjustments post-COVID-19 and geopolitical tensions influencing raw material...

The heparin market is expanding as the prevalence of chronic diseases, cardiovascular conditions, blood transfusions, and age-related health issues increases the need for anticoagulant therapies. The market was valued at USD 7.6 billion in 2023 and is projected to grow from USD 8.1 billion in 2026 to USD 9.0 billion by 2030, registering a CAGR of 2.7% from 2024 to 2030. Rising demand for whole...

The United States is the largest national market for low molecular weight (LMW) heparin in North America, driven by the high burden of venous thromboembolism (VTE), deep vein thrombosis, pulmonary embolism, and acute coronary syndromes, along with an aging population and a large surgical and orthopedic patient base. Enoxaparin, dalteparin, and fondaparinux-class alternatives are widely used for...